Gilotrif 40 mg/1

Gilotrif Tablet, film coated is a product of Boehringer Ingelheim

Group: Approved Protein Kinase Inhibitors

Name: Gilotrif

Dosage: Tablet, film coated

Strength: 40 mg/1

Route: Oral

Pharmaceutical company : Boehringer Ingelheim

You can also find other alternative products such as : Giotrif (20 mg) from Boehringer Ingelheim (Canada) Ltd Ltee Gilotrif (20 mg/1) from Boehringer Ingelheim Gilotrif (30 mg/1) from Boehringer Ingelheim Gilotrif (30 mg/1) from Boehringer Ingelheim Gilotrif (40 mg/1) from Boehringer Ingelheim Gilotrif (20 mg/1) from Boehringer Ingelheim

Indication: Afatinib is a kinase inhibitor indicated as monotherapy [3] for the first-line [Label] treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test [Label], and (b) adult patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy [Label]. Recently, as of January 2018, the US FDA approved a supplemental New Drug Application for Boehringer Ingelheim's Gilotrif (afatinib) for the first line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [4]. The new label includes data on three additional EGFR mutations: L861Q, G719X and S768I [4].

Category:

  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • BCRP/ABCG2 Inhibitors
  • BCRP/ABCG2 Substrates
  • Kinase Inhibitor
  • P-glycoprotein/ABCB1 Inhibitors
  • P-glycoprotein/ABCB1 Substrates
  • Protein Kinase Inhibitors
  • Tyrosine Kinase Inhibitors
  • Food Interactions; When given with a high-fat meal, Cmax decreases by 50% and AUC by 39% relative to the fasted state.

    Afatinib Definition:
    Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [4]. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim [4].

    More Gilotrif 40 mg/1

    Gilotrif

    Therapeutic indications Afatinib is used to treat a certain type of lung cancer (non-small cell lung cancer) that has spread to other parts of the body

    A very serious allergic reaction to this drug is rare..Mouth sores, pain/redness/swelling of lips, dry/itchy skin, acne, nose bleed, runny nose, nausea/vomiting, or loss of appetite may occur.. If you notice other effects not listed above, contact your doctor or pharmacist..
    If you become pregnant or think you may be pregnant, tell your doctor right away..**Precautions**Before taking afatinib, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.. Because of the possible risk to the infant, breast-feeding while using this drug and for 2 weeks after stopping this drug is not recommended..


    GILOTRIF Rx

    Therapeutic indications Respiratory and thoracic cancers


    Severe renal or hepatic impairment; monitor and adjust dose (see Adults).. Interactions: See Adults.. John’s wort)..


    GILOTRIF Rx

    Therapeutic indications Respiratory and thoracic cancers


    Withhold for prolonged diarrhea Grade ≥2 lasting for ≥2 consecutive days while taking antidiarrheal, prolonged cutaneous reaction Grade ≥2 (lasting >7 days) or intolerable, during evaluation of suspected ILD, renal dysfunction Grade ≥2, or worsening liver function.. John’s wort).. Pregnancy (avoid)..


    Effects of Gilotrif 40 mg/1 by reaction with another drug or drugs

  • The serum concentration of Afatinib can be increased when it is combined with Midazolam.
  • The serum concentration of Afatinib can be increased when it is combined with Acetaminophen.
  • The serum concentration of Afatinib can be increased when it is combined with Posaconazole.
  • The serum concentration of Afatinib can be increased when it is combined with Tolvaptan.
  • The serum concentration of Afatinib can be increased when it is combined with Voxilaprevir.
  • The serum concentration of Sumatriptan can be increased when it is combined with Afatinib.
  • The serum concentration of Afatinib can be increased when it is combined with Pethidine.
  • The serum concentration of Vinorelbine can be increased when it is combined with Afatinib.
  • The serum concentration of Afatinib can be increased when it is combined with Sorafenib.
  • The serum concentration of Afatinib can be increased when it is combined with Propofol.
  • The serum concentration of Afatinib can be increased when it is combined with Terazosin.
  • The serum concentration of Mitomycin can be increased when it is combined with Afatinib.
  • The serum concentration of Clonidine can be increased when it is combined with Afatinib.
  • The serum concentration of Morphine can be increased when it is combined with Afatinib.
  • The serum concentration of Afatinib can be increased when it is combined with Nilotinib.
  • The serum concentration of Afatinib can be increased when it is combined with Ergonovine.
  • The serum concentration of Afatinib can be increased when it is combined with Fluconazole.
  • The serum concentration of Afatinib can be increased when it is combined with Terfenadine.
  • The serum concentration of Afatinib can be increased when it is combined with Idelalisib.
  • The serum concentration of Afatinib can be increased when it is combined with Rolapitant.